Anti-ROR2 antibodies, antibody fragments, their immunoconjucates and uses thereof

Inventors

Short, Jay M. • Chang, Hwai Wen • Frey, Gerhard

Assignees

Bioatla Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-11879011-B2

Patent

Publication Date

2024-01-23

Expiration Date


Abstract

A polypeptide having a heavy chain variable region and/or a light chain variable region that specifically binds to Ror2 protein, as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region, are provided. Pharmaceutical compositions and kits comprising the polypeptide or antibodies and antibody fragments containing the polypeptide are also provided.

Core Innovation

The disclosure relates to a human or humanized antibody or antibody fragment that specifically binds to ROR2 protein. The antibody includes a heavy chain variable region with three complementarity determining regions having H1, H2, and H3 sequences, and a light chain variable region with three complementarity determining regions having L1, L2, and L3 sequences. The H1, H2, H3 and L1, L2, L3 sequences are defined by SEQ ID NOs and variable position rules with constrained amino-acid options, and the antibody or fragment includes only one single point mutation in one of the heavy and light chain complementarity determining regions, determined in comparison with the parent polypeptide.

The disclosure also addresses antibody-drug conjugate drug loading and heterogeneity arising from different conjugation outcomes. Varying numbers of drug moieties yield heterogeneous ADC mixtures, which are quantified by dual ELISA and analyzed and separated by MS and HPLC, with potential isolation of homogeneous ADCs. The disclosure therefore addresses controlled ADC drug loading and characterization of prepared conjugates.

The disclosure further relates to diagnostic/detection uses and broad pharmaceutical and therapeutic coverage for ROR2-associated diseases, including anti-ROR2 antibodies used as detection agents for imaging and quantification across multiple cancer types. It also includes immunoconjugates and ADCs, mention of tumor efficacy dependent on pH and linker/toxin conjugation, and pharmaceutical compositions for ROR2-expressing cancers.

Claims Coverage

The independent claim coverage centers on one ROR2-binding human or humanized antibody or antibody fragment with precisely defined heavy-chain and light-chain variable-region complementarity determining region sequences, limited to only one single point mutation versus a parent polypeptide. Additional coverage extends to tumor-vs-non-tumor binding selectivity, immunoconjugates, and related compositions and uses.

Single-point-mutated ROR2-binding antibody defined by heavy- and light-chain CDR sequence patterns

A human or humanized antibody or antibody fragment specifically binding to ROR2 protein, comprising a heavy chain variable region with H1, H2, H3 sequences and a light chain variable region with L1, L2, L3 sequences, where the antibody or fragment has only one single point mutation in one of the heavy and light chain complementarity determining regions, determined in comparison with the parent polypeptide.

Tumor microenvironment preferential binding selectivity

An antibody or antibody fragment binds to ROR2 with a binding affinity in the tumor microenvironment that is at least about 3:1 relative to its binding affinity to ROR2 in the non-tumor microenvironment.

Immunoconjugate format using the defined ROR2-binding antibody or antibody fragment

An immunoconjugate includes the antibody or antibody fragment described in the defined ROR2-specific CDR and single-point-mutation framework.

Immunoconjugate cytotoxic payload agent classes

In the immunoconjugate, the at least one agent is selected from maytansinoids, auristatins, dolastatins, calicheamicin, pyrrolobenzodiazepines, and anthracyclines.

The claim coverage is anchored to an ROR2-specific human or humanized antibody or fragment defined by constrained CDR-H and CDR-L sequence patterns plus a restriction to a single point mutation versus a parent polypeptide, with dependent refinements addressing tumor microenvironment preferential binding and extension into immunoconjugates with specified cytotoxic payload agent classes.

Stated Advantages

Tumor microenvironment preferential binding selectivity relative to non-tumor microenvironment.

Conditionally defined binding favoring the tumor microenvironment characterized by lower pH.

Controlled ADC drug loading and management of heterogeneity arising from different conjugation outcomes.

Documented Applications

Diagnostic and therapeutic settings using the described pharmaceutical compositions and kits.

Therapeutic use of immunoconjugates or antibody-drug conjugates that include the ROR2-binding antibody or antibody fragment conjugated to cytotoxic payload agent classes.

Diagnostic/detection uses, including detection agents for imaging and quantification across multiple cancer types.

Pharmaceutical compositions for ROR2-expressing cancers.

Immunoconjugates and ADCs for ROR2-associated diseases.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.